i n f l a r x

Loading

Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

Press Release
Home Investors Press Releases Press Release

InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

Sep 08, 2021

Time to read 4 Minutes
  Download PDF


Back